Company intelligence / Profile preview

Meiji Holdings Co., Ltd.

Chuo-ku, Tokyo, Japanmeiji.com ↗

Ownership: Public · 2269
Employees: ~5500
Development stage: Commercial

Overview

Meiji has multiple commercial products including antibacterial drugs, CNS medications, and recently obtained the world's first marketing approval for a self-amplifying mRNA vaccine against COVID-19 (Kostaive®). They also have launched a selective ROCK2 inhibitor (belumosudil mesilate) for chronic GVHD and an HDAC inhibitor (tucidinostat) for ATLL and PTCL in Japan[9].

Therapeutic areas: OncologyImmunologyHematologyPsychiatryDermatologyNeurologyInfectious Diseases
Modalities: Small moleculesmRNA vaccinesantibacterial drugsbiologics
Industry: Biotech

Drug pipeline

10 assets

Bifidobacterium bifidum OLB6378

Preclinical

9 more assets in the full pipeline.

Request access →

Partnerships

MPM BioImpactKOI The Cambodia

Beyond the preview

Go deeper on Meiji Holdings Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meiji Holdings Co., Ltd..

Explore the full profile